JACOBSON PHARMA (02633) and JBM HEALTHCARE (02161): ULFERTS Pharmaceuticals and ULFERTS Pharmaceuticals (Hong Kong) have entered into a 2025 ULFERTS Pharmaceuticals licensing agreement.

JACOBSON PHARMA (02633) and JBM HEALTHCARE (02161) jointly announced that, as the 2020 license agreement will expire on November 30, 2025, ULFERTS Pharmaceuticals and ULFERTS Pharmaceuticals (Hong Kong) entered into a 2025 ULFERTS Pharmaceuticals License Agreement on October 28, 2025. ULFERTS Pharmaceuticals agreed to allow ULFERTS Pharmaceuticals (Hong Kong) to use certain factories in accordance with the terms and conditions of the 2025 ULFERTS Pharmaceuticals License Agreement, with the period starting from December 1, 2025 to January 27, 2028 (including the first and last days), and a monthly license fee of HK$247,000. It is understood that ULFERTS Pharmaceuticals Limited is an indirect wholly-owned subsidiary of Jacobson Pharma. ULFERTS Pharmaceuticals (Hong Kong) Limited is an indirect wholly-owned subsidiary of JBM HEALTHCARE. Since 2007, ULFERTS Pharmaceuticals has been leasing factories in the Science Park for the manufacturing of pharmaceutical products. Under the lease agreement, ULFERTS Pharmaceuticals may, with prior written approval from the Science Park, license certain entities to use the factories. This licensing arrangement under the 2025 ULFERTS Pharmaceuticals License Agreement will bring rental income to ULFERTS Pharmaceuticals for the unused factory space, and provide suitable manufacturing facilities for ULFERTS Pharmaceuticals (Hong Kong). The relocation of ULFERTS Pharmaceuticals (Hong Kong) existing facilities that comply with pharmaceutical quality management standards is costly and time-consuming. Therefore, the 2025 ULFERTS Pharmaceuticals License Agreement allows ULFERTS Pharmaceuticals (Hong Kong) to continue operations without interruption and avoid relocation expenses.